


Ciclopirox

Cat. No.:	HY-B0450
CAS No.:	29342-05-0
Molecular Formula:	C ₁₂ H ₁₇ NO ₂
Molecular Weight:	207.27
Target:	Fungal; Autophagy; Ferroptosis; Bacterial
Pathway:	Anti-infection; Autophagy; Apoptosis
Storage:	<div> Powder -20°C 3 years </div> <div> 4°C 2 years </div> <div> In solvent -80°C 2 years </div> <div> -20°C 1 year </div>



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (482.46 mM; Need ultrasonic)					
	Preparing Stock Solutions	<div>Solvent Concentration</div>	<div>Mass</div>	1 mg	5 mg	10 mg
		1 mM		4.8246 mL	24.1231 mL	48.2462 mL
		5 mM		0.9649 mL	4.8246 mL	9.6493 mL
		10 mM		0.4825 mL	2.4123 mL	4.8246 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (12.06 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (12.06 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil					
	Solubility: ≥ 2.5 mg/mL (12.06 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Ciclopirox (HOE296b) is a synthetic and orally active antifungal agent that can be used for superficial mycoses research. Ciclopirox olamine has a very broad spectrum of activity and inhibits dermatophytes, yeasts, molds, and many Gram-positive and Gram-negative species pathogenic. Ciclopirox also has anticancer and anti-inflammatory effect ^{[1][2][3]} .
In Vitro	Ciclopirox (10 μM, 18 h) inhibits HUVEC proliferation and angiogenesis ^[4] . Ciclopirox (0-10 μM, 20 h) inhibits deoxyhypusine hydroxylation in HUVECs ^[4] . Ciclopirox (0-40 μM, 72 h) shows anti-tumor activity in H1299 and 95D cells (decreases cell viability, with IC ₅₀ s of 11.13 and

	<p>4.136 μM respectively), and inhibits cell migration and invasion^[5].</p> <p>Ciclopirox (0-40 μM, 48 h) arrests both H1299 and 95D cells in G1 phase, decreases Cyclin D1 and CDK4 protein level in H1299 and 95D cells^[5].</p> <p>Ciclopirox (0-20 μM) induces cell aerobic glycolysis, impairs mitochondrial functions and enhances the generation of ROS in H1299 and 95D cells^[5].</p> <p>Ciclopirox (0-40 μM, 48 h) activates PERK-dependent ER stress in CRC cells (HCT-8, HCT-8/5-FU, and DLD-1 cells)^[6].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
In Vivo	<p>Ciclopirox (20 mg/kg, i.p.) reduces tumor size in mouse H1299 xenograft model, and reduces tumor cell proliferation (Ki67 staining) and increases apoptosis (Cleaved-Caspase 3 and TUNEL staining)^[5].</p> <p>Ciclopirox (25 mg/kg, p.o., daily) also inhibits tumor growth in human breast cancer MDA-MB231 xenografts in mice^[6].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

CUSTOMER VALIDATION

- Clin Transl Med. 2022 Aug;12(8):e999.
- Pharmacol Res. 7 January 2022, 106046.
- Front Pharmacol. 2021 May 10;12:670224.
- Eur J Pharmacol. 2022 Jul 19;175156.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Clement PM, et al. The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro. Int J Cancer. 2002 Aug 1;100(4):491-8.
- [2]. Lu J, et al. Ciclopirox targets cellular bioenergetics and activates ER stress to induce apoptosis in non-small cell lung cancer cells. Cell Commun Signal. 2022 Mar 24;20(1):37.
- [3]. Zhou H, et al. The antitumor activity of the fungicide ciclopirox. Int J Cancer. 2010 Nov 15;127(10):2467-77.
- [4]. Niewerth, M., et al., Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother, 2003. 47(6): p. 1805-17.
- [5]. Leem, S.H., et al., The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae. Mol Cells, 2003. 15(1): p. 55-61.
- [6]. Ratnavel, R.C., R.A. Squire, and G.C. Boorman, Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrheic dermatitis. J Dermatolog Treat, 2007. 18(2): p. 88-96.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA